title: Immune pancytopenia after chemotherapy in a patient with diffuse large B-cell lymphoma.
abstract: During treatment for malignant lymphoma, cytopenia can develop for several reasons. In the treatment of cytopenia, various possibilities should be considered because inadequate treatment causes exacerbation of cytopenia and can lead to fatal conditions, such as infection and bleeding. Herein, we describe immune pancytopenia 3 months after the last exposure to chemotherapy in a patient with diffuse large B-cell lymphoma (DLBCL). She suffered from severe pancytopenia after two courses of rituximab and bendamustine therapy for a second relapse of DLBCL. Immune pancytopenia was diagnosed with bone marrow tests and the presence of autoantibodies; it promptly resolved after initiation of prednisolone therapy. Clinicians should be aware of immune cytopenia and monitor for it carefully, even if patients have already finished chemotherapy treatment.
authors.affiliation: Department of Internal Medicine, Asahi General Hospital, Asahi, Chiba, Japan.
authors.forename: Kazuyo
authors.initials: K
authors.lastname: Nagashima
authors.affiliation: Department of Hematology, Asahi General Hospital, Asahi, Chiba, Japan.
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Tanaka
authors.affiliation: Department of Hematology, Asahi General Hospital, Asahi, Chiba, Japan.
authors.forename: Yurie
authors.initials: Y
authors.lastname: Nagai
authors.affiliation: Department of Hematology, Asahi General Hospital, Asahi, Chiba, Japan.
authors.forename: Yasumasa
authors.initials: Y
authors.lastname: Sugita
mesh_terms: D000369:Aged, 80 and over; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects*; D044466:Asian People; D000069461:Bendamustine Hydrochloride / Q000008:administration & dosage / Q000009:adverse effects*; D001853:Bone Marrow / Q000473:pathology; D005260:Female; D006801:Humans; D007564:Japan / Q000208:ethnology; D016403:Lymphoma, Large B-Cell, Diffuse / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D009364:Neoplasm Recurrence, Local; D010198:Pancytopenia / Q000097:blood / Q000139:chemically induced* / Q000188:drug therapy; D011239:Prednisolone / Q000627:therapeutic use*; D000069283:Rituximab / Q000008:administration & dosage / Q000009:adverse effects*; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D000970:Antineoplastic Agents; D000069283:Rituximab; D000069461:Bendamustine Hydrochloride; D011239:Prednisolone